SpecificationsOrganism*Homo sapiens*SexNot applicableSequencer or array typeIllumina HumanHT-12 V4.0 expression beadchipData formatRaw and normalized data in plain text format.Experimental factorsMonocytes on day 0 vs. monocyte derived cells (MDCs) on day 7Experimental featuresExpression profiling of CD14 positive monocytes isolated from CLL patient PBMCs on day 0 and from MDCs from CLL PBMCs cultured for seven days to identify differences between the MDCs derived from sensitive or resistant CLL patients and differences in MDCs pre and post in vitro cultureConsentAll samples were obtained after informed consentSample source locationBrisbane, Australia

1. Direct link to deposited data {#s0005}
================================

Deposited data can be found here: <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71409>

2. Data {#s0010}
=======

Whole genome transcriptomics data from CD14 positive monocytes isolated from CLL patient peripheral blood mononuclear cells (PBMCs) for four patients and monocyte derived cells from CLL PBMCs cultured for seven days for seven patients.

3. Experimental design, materials and methods {#s0015}
=============================================

3.1. Patient samples and cell purification {#s0020}
------------------------------------------

Peripheral blood from CLL patients was collected after informed consent according to protocols approved by the Princess Alexandra Hospital (PAH) Human Research Ethics Committee. Patient characteristics are outlined in [Table 1](#t0005){ref-type="table"}. PBMCs were isolated by density-gradient centrifugation over Histopaque-1077 and red blood cells lysed using ammonium chloride. To determine antibody sensitivity, CLL PBMCs were cultured in RPMI + 10% fetal calf serum in the presence of LEAF Purified anti-human CD62L antibody (DREG56; 0.1 μg/ml; Biolegend) and CLL cell survival examined after seven days using trypan blue exclusion [@bb0020]. CLL patients\' responses were classified as sensitive if survival ≤ 40% or resistant if survival ≥ 70% of untreated cultures ([Fig. 1](#f0005){ref-type="fig"}A).

For day 0 samples, monocytes were isolated from CLL PBMCs using MACS cell separation and CD14 MicroBeads according to manufacturer\'s instructions (Miltenyi Biotec). Purity of samples was examined by flow cytometry and all samples ≥ 85% based on CD14 positivity. For day 7 monocyte-derived cells (MDCs), CLL PBMCs were maintained in RPMI 10% FCS for seven days to allow maturation of MDCs and MDCs isolated after removal of non-adherent cells. Representative images showing MDC morphology from an antibody sensitive and antibody resistant CLL patient is shown in [Fig. 1](#f0005){ref-type="fig"}B. CD14 positive monocytes from 2 sensitive and 2 resistant patients and MDCs from 4 sensitive and 3 resistant CLL patients are used in this study.

3.2. Gene expression analysis {#s0025}
-----------------------------

Total RNA from monocytes and MDCs was extracted with Bioline Isolate II RNA Micro kit in accordance with the prescribed protocol provided with the kit (Bioline). The integrity of the isolated RNA was determined using Agilent RNA 6000 Pico kit (Agilent Technologies) on an Agilent Bioanalyzer. Microarray profiling was performed using Illumina HumanHT-12 v4 Expression BeadChips (Illumina) as per the manufacturer\'s protocol. Probe intensities have been background corrected using negative control probes and quantile normalized using the neqc [@bb0025] function of the limma [@bb0030] package.

Microarray data have been uploaded to Gene Expression Omnibus under the reference: [GSE71409](ncbi-geo:GSE71409){#ir0020}. The original CEL files from GEO accession [GSE5099](ncbi-geo:GSE5099){#ir0025} [@bb0035], [@bb0040] were downloaded. These contain gene expression data for freshly isolated monocytes at day 0, macrophages at day 3 and day 7, Interferon Gamma and LPS treated macrophages and IL-4 treated macrophages. These experiments were performed on the Affymetrix Human Genome U133A Array. Arrays from [GSE5099](ncbi-geo:GSE5099){#ir0030} and the current study were preprocessed and normalized with platform specific tools: the Affymetrix arrays were normalized using the RMA algorithm [@bb0045], [@bb0050] and the Illumina arrays were quantile normalized after applying the VST algorithm [@bb0055], [@bb0060]. Large platform specific batch effects were observed between the two datasets, so an unsupervised empirical Bayes method was used to remove these batch effects after as implemented in the 'virtualArray' package [@bb0065]. The two datasets were merged on common genes after multiple probes that mapped to the same gene were collapsed by taking the median expression value per sample. Genes that had no expression detected in any sample across both studies (as indicated with a detection p-value \< 0.01) were removed from the data.

4. Conclusion {#s0030}
=============

MDCs isolated from PBMCs of CLL patients are frequently referred to as nurse like cells and are known to promote the survival of malignant B cells in culture and to mediate responses to therapeutic antibodies [@bb0005], [@bb0010], [@bb0015]. We have compared the transcriptomic profiles of MDCs that are sensitive to, or resistant to, therapeutic antibodies.

Transcriptomic profiling of freshly isolated monocytes and 7 day adherent MDCs from 4 freshly isolated and 7 adherent (7 day) patient cultures failed to find statistically significant differentially expressed transcripts that discriminate between MDCs derived from sensitive *vs* resistant patients. However, after normalization and correction for platform-specific batch effects, we were able to compare our dataset to that of a previously published dataset of MDCs cultured for 0, 3 or 7 days [@bb0035]. Clustering of our transcript data and that of Martinez et al. [@bb0035] reveals marked similarities between the two datasets ([Fig. 2](#f0010){ref-type="fig"}A & B). The day 0 monocytes of both studies cluster together and are more similar to one another than any other cell type. Moreover, while the day 7 adherent MDCs from the current study, form their own distinct cluster they share similarities with the day 3, day 7 and M2 macrophages of Martinez, et al. [@bb0035]. These data confirm that following 7 days culture our MDCs are enriched for macrophages/NLCs which display an M2-like transcript profile.

![Differential sensitivity to CD62L antibody *in vitro*. (A) CLL PBMCs were cultured in the presence of anti-human CD62L antibody (DREG56; 0.1 μg/ml) and cell survival examined after 7 days using trypan blue exclusion. CLL cell survival was normalized to untreated CLL PBMCs survival. (B) CLL PBMCs were cultured for 7 days before non-adherent cells were removed by gentle agitation and MDCs were visualized by Giemsa staining (magnification = 20 ×). A representative image from one sensitive and one resistant patient is shown.](gr1){#f0005}

![CLL MDCs display characteristics similar to M2 macrophages. Microarray data from monocytes on day 0 and MDCs on day 7 from sensitive and resistant patients were compared to those from GEO accession [GSE5099](ncbi-geo:GSE5099){#ir0005}. Datasets were merged on common genes and the program 'virtualArray' was applied to remove platform specific batch effects using an unsupervised empirical Bayes algorithm. (A) multidimensional scaling plot and (B) heatmap of the top 500 genes with the most variable expression. Both figures show a similar pattern: the day 0 monocytes of the current study are most similar to the day 0 monocytes obtained by Martinez et al. (ref. [@bb0035]) while the day 7 macrophages of the current study cluster close to the day 7 macrophages and M2 macrophages of Martinez et al. (ref. [@bb0035]). M1 cells have a gene expression profile that is dissimilar to any other cell type either in the previously published study or the current study.](gr2){#f0010}

###### 

Patient clinical features.

  Patient code   Age   Sex   CD38       Zap 70     IgVH status   FISH
  -------------- ----- ----- ---------- ---------- ------------- -----------------------------
  CLL261         40    M     Negative   Positive   Unmutated     13q deletion & 17p deletion
  CLL292         77    M     Positive   Positive   ND            11q deletion & 13q deletion
  CLL315         75    F     Negative   Positive   Mutated       Trisomy 12
  CLL338         69    F     Negative   Positive   Mutated       ND
  CLL395         70    F     Negative   Positive   ND            Normal karyotype
  CLL398         59    F     Negative   Negative   Mutated       13q deletion
  CLL399         41    M     Positive   Positive   Mutated       17p deletion + monosomy 12
  CLL404         88    M     Positive   Positive   Unmutated     13q deletion
  CLL409         72    M     Negative   Positive   Mutated       13q deletion
  CLL414         67    M     Positive   Positive   Unmutated     17p deletion & 13q deletion
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